|
Jason Kritzer and Samantha Pandolfi, co-managers of the fund,
highlighted Vertex Pharmaceuticals, Zoetis and Shire for future
outperformance in an article in Barron's.
Kritzer said he expects to see Vertex increase its revenue by at
least 20 percent in 2017 and 30 percent in 2018, with per-share
profit potentially doubling this year and again next year. He
sees the stock price rising to "between $152 and $155."
Vertex closed at $130.99 on Friday.
Pandolfi says she sees 15 percent upside for drugmaker Zoetis
and 40 percent upside for Dublin-based drugmaker Shire.She said
Shire's stock price has been held back by investor concerns the
company is losing ground to other manufacturers of hemophilia
drugs, which Shire relies on for a large portion of its annual
revenue.
"If the hemophilia fears persist, it could take two to three
years to deliver those returns," she said. "If the fears abate,
it will happen sooner."
The pair said that the pharmaceutical and biotechnology
industries have been proactive in the face of uncertainty
surrounding the possible repeal of the Affordable Care Act,
noting also that "The leaked draft executive order on drug
pricing reads favorably for industries. With repeal and replace
[of the Affordable Care Act], depending on how things shake out,
hospitals are the big losers long term, due to cuts in
Medicaid."
(Reporting by Dion Rabouin; Editing by Andrea Ricci)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
